Physician profile
Daryl L Jacobs
NPI 1770686958
$6,515.12
in general payments reported to CMS, 2019-2025
36 companies · $305 in 2025
The $305 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,778 · 2020: $1,470 · 2021: $1,829 · 2022: $739 · 2023: $144 · 2024: $250 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $699.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,028.06 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Janssen Pharmaceuticals, INC | $746.02 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $588.67 | 2019-2025 | Tezspire |
| Medtronic Vascular, INC. | $509.88 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $315.55 | 2019-2021 | |
| Amgen INC. | $311.45 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $299.37 | 2019-2022 | |
| United Therapeutics Corporation | $284.12 | 2019-2025 | Tyvaso, Tyvaso |
| Regeneron Healthcare Solutions, INC. | $231.65 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $212.68 | 2019-2025 | Uptravi, Opsumit |
| Mylan Specialty L.P. | $196.35 | 2019-2021 | |
| Boston Scientific Corporation | $195.01 | 2019-2022 | |
| Pfizer INC. | $180.64 | 2019-2022 | |
| Grifols USA, LLC | $169.66 | 2019-2025 | Prolastin-C Liquid |
| Amarin Pharma, INC. | $163.44 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $161.19 | 2019-2024 | Smartvest |
| Genzyme Corporation | $153.42 | 2019-2024 | |
| Abiomed | $143.86 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $112.24 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $83.13 | 2019-2025 | Winrevair |
| Philips North America LLC | $62.09 | 2019 | |
| Glaxosmithkline, LLC. | $44.10 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $43.02 | 2019-2022 | |
| Edwards Lifesciences Corporation | $41.22 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.99 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.36 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $23.38 | 2019 | |
| Bardy Diagnostics, INC. | $20.00 | 2020 | |
| Gilead Sciences, INC. | $19.76 | 2021 | |
| Baxter Healthcare | $19.27 | 2023 | Hillrom - Life 2000 Ventilation System |
| Genentech USA, INC. | $18.09 | 2024 | Xolair |
| Azurity Pharmaceuticals, INC. | $16.00 | 2025 | Alvesco |
| Verona Pharma, INC. | $15.81 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $15.53 | 2025 | Yupelri |
| Abbott Laboratories | $14.44 | 2021 | |
| Esperion Therapeutics, INC. | $13.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daryl Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.